Fungal Endophthalmitis: Clinical Characteristics, Pathogens, and Factors Affecting Visual Outcome
Abstract
:1. Introduction
2. Results
2.1. Clinical Characteristics
2.2. Microbiology Results
2.3. Treatment and Outcomes
2.4. Visual Outcome
3. Discussion
4. Materials and Methods
4.1. Study Population
4.2. Pars Plana Vitrectomy
4.3. Treatment
4.4. Specimen Collection and Culture
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Haseeb, A.A.; Elhusseiny, A.M.; Siddiqui, M.Z.; Ahmad, K.T.; Sallam, A.B. Fungal endophthalmitis: A comprehensive review. J. Fungi 2021, 7, 996. [Google Scholar] [CrossRef] [PubMed]
- Durand, M.L. Bacterial and fungal endophthalmitis. Clin. Microbiol. Rev. 2017, 3, 597–613. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.J.; Sun, M.H.; Chen, Y.P.; Chen, Y.H.; Wang, N.K.; Liu, L.; Chao, A.N.; Wu, W.C.; Hwang, Y.S.; Lai, C.C. Endogenous fungal endophthalmitis: Causative organisms, treatments, and visual outcomes. J. Fungi 2022, 8, 641. [Google Scholar] [CrossRef]
- Lupia, T.; Corcione, S.; Fea, A.M.; Reibaldi, M.; Fallico, M.; Petrillo, F.; Galdiero, M.; Scabini, S.; Polito, M.S.; Ciabatti, U.; et al. Exogenous fungal endophthalmitis: Clues to Aspergillus aetiology with a pharmacological perspective. Microorganisms 2021, 9, 74. [Google Scholar] [CrossRef]
- Priluck, A.Z.; Huang, P.; Breazzano, M.P. Outcomes and Clinical Features Predictive of Fungal Endophthalmitis. Am. J. Ophthalmol. 2023, 251, 104–114. [Google Scholar] [CrossRef]
- Narnaware, S.H.; Bawankule, P.K.; Sontakke, S. Misdiagnosed case of fungal endophthalmitis. Eye 2023, 1. [Google Scholar] [CrossRef]
- Lupia, T.; Corcione, S.; Fea, A.M.; Reibaldi, M.; Fallico, M.; Petrillo, F.; Galdiero, M.; Scabini, S.; Polito, M.S.; Ciabatti, U.; et al. The diagnosis and treatment of fungal endophthalmitis: An update. Diagnostics 2022, 12, 679–693. [Google Scholar]
- Riddell, J.; Comer, G.M.; Kauffman, C.A. Treatment of endogenous fungal endophthalmitis: Focus on new antifungal agents. Clin. Infect. Dis. 2011, 52, 648–653. [Google Scholar] [CrossRef] [PubMed]
- Azhari, J.; Tetelbom, P.S.; Sallam, A.B. The Role of Adjuvant Systemic and Intravitreal Corticosteroids in Fungal Endophthalmitis Treatment. J. Fungi 2023, 28, 1147. [Google Scholar] [CrossRef] [PubMed]
- Anand, A.; Madhavan, H.; Neelam, V.; Lily, T. Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology 2001, 108, 326–330. [Google Scholar] [CrossRef] [PubMed]
- Tarai, B.; Gupta, A.; Ray, P.; Shivaprakash, M.R.; Chakrabarti, A. Polymerase chain reaction for early diagnosis of post-operative fungal endophthalmitis. Indian J. Med. Res. 2006, 123, 671–678. [Google Scholar]
- Anand, A.R.; Madhavan, H.N.; Sudha, N.V.; Therese, K.L. Polymerase chain reaction in the diagnosis of Aspergillus endophthalmitis. Indian J. Med. Res. 2001, 114, 133–140. [Google Scholar]
- Duan, F.; Yang, Y.; Yuan, Z.; Zheng, Y.; Cheng, Z.; Lin, X. Clinical Features and Visual Acuity Outcomes in Culture-Positive Endogenous Fungal Endophthalmitis in Southern China. J. Ophthalmol. 2017, 2017, 3483497. [Google Scholar] [CrossRef]
- Zhang, H.; Liu, Z. Endogenous endophthalmitis: A 10-year review of culture-positive cases in northern China. Ocul. Immunol. Inflamm. 2010, 18, 133–138. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Chang, Y.; Zhang, Y.; Yang, R.; Shi, H.; Zhang, M. Bilateral endogenous fungal endophthalmitis: A case report. Medicine 2023, 102, e33585. [Google Scholar] [CrossRef]
- Khambati, A.; Wright, R.E., 3rd; Das, S.; Pasula, S.; Sepulveda, A.; Hernandez, F.; Kanwar, M.; Chandrasekar, P.; Kumar, A. Aspergillus endophthalmitis: Epidemiology, pathobiology, and current treatments. J. Fungi 2022, 8, 656. [Google Scholar] [CrossRef]
- Modjtahedi, B.S.; Finn, A.P.; Papakostas, T.D.; Durand, M.; Husain, D.; Eliott, D. Intravenous Drug Use-Associated Endophthalmitis. Ophthalmol. Retin. 2017, 1, 192–199. [Google Scholar] [CrossRef] [PubMed]
- Chakrabarti, A.; Shivaprakash, M.R.; Singh, R.; Tarai, B.; George, V.K.; Fomda, B.A.; Gupta, A. Fungal endophthalmitis: Fourteen years’ experience from a center in India. Retina 2008, 10, 1400–1407. [Google Scholar] [CrossRef] [PubMed]
- Wykoff, C.C.; Flynn, H.W., Jr.; Miller, D.; Scott, I.U.; Alfonso, E.C. Exogenous Fungal Endophthalmitis: Microbiology and Clinical Outcomes. Ophthalmology 2008, 115, 1501–1507. [Google Scholar] [CrossRef]
- Rao, N.A.; Hidayat, A. A comparative clinicopathologic study of endogenous mycotic endophthalmitis: Variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. Trans. Am. Ophthalmol. Soc. 2000, 98, 183–194. [Google Scholar]
- Schiedler, V.; Scott, I.U.; Flynn, H.W., Jr.; Davis, J.L.; Benz, M.S.; Miller, D. Culture-proven endogenous endophthalmitis: Clinical features and visual acuity outcomes. Am. J. Ophthalmol. 2004, 137, 725–731. [Google Scholar]
- Forster, R.K. Etiology and diagnosis of bacterial postoperative endophthalmitis. Ophthalmology 1978, 85, 320–326. [Google Scholar] [CrossRef]
- Sen, S.; Lalitha, P.; Mishra, C.; Parida, H.; Rameshkumar, G.; Kannan, N.B.; Ramasamy, K. Post-cataract surgery fungal endophthalmitis: Management outcomes and prognostic factors. Ocul. Immunol. Inflamm. 2021, 29, 1530–1536. [Google Scholar] [CrossRef]
- Behera, U.C.; Budhwani, M.; Das, T.; Basu, S.; Padhi, T.R.; Barik, M.R.; Sharma, S. Role of early vitrectomy in the treatment of fungal endophthalmitis. Retina 2018, 38, 1385–1392. [Google Scholar] [CrossRef] [PubMed]
- Dave, V.P.; Pappuru, R.R.; Pathengay, A.; Gupta, R.; Joseph, J.; Sharma, S.; Das, T. Aspergillus endophthalmitis: Clinical presentations and factors determining outcomes. Asia Pac. J. Ophthalmol. 2020, 9, 9–13. [Google Scholar] [CrossRef]
- Gao, Y.; Chen, N.; Dong, X.G.; Yuan, G.Q.; Yu, B.; Xie, L.X. Surgical management of fungal endophthalmitis resulting from fungal keratitis. Int. J. Ophthalmol. 2016, 9, 848–853. [Google Scholar] [PubMed]
- Zhuang, H.; Ding, X.; Zhang, T.; Chang, Q.; Xu, G. Vitrectomy combined with intravitreal antifungal therapy for posttraumatic fungal endophthalmitis in eastern China. BMC Ophthalmol. 2020, 20, 435. [Google Scholar] [CrossRef]
- Hariprasad, S.M.; Mieler, W.F.; Holz, E.R.; Gao, H.; Kim, J.E.; Chi, J.; Prince, R.A. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 2004, 122, 42–47. [Google Scholar] [CrossRef] [PubMed]
Clinical Characteristics | Total 92/102 | Post-Trauma 52/52 | Postoperative 7/7 | Endogenous 13/16 | Other 20/27 | p Value |
---|---|---|---|---|---|---|
Male/Female | 61/31 | 40/12 | 4/3 | 7/6 | 10/10 | 0.08 |
Age in years (years) (mean, SD) | 44.4 ± 19.8 | 39.4 ± 20.7 | 59.1 ± 17.4 | 44.5 ± 16.1 | 52.0 ± 16.0 | 0.16 |
Infected eyes | ||||||
Left eye | 42 (45.6%) | 19 (36.5%) | 6 (85.7%) | 8 (61.5%) | 9 (45.0%) | <0.001 |
Right eye | 42 (43.5%) | 33 (63.5%) | 1 (14.3%) | 2 (15.4%) | 4 (20.0%) | |
Both eyes | 10 (10.9%) | 3 (23.1%) | 7 (35.0%) | |||
Underlying disease | ||||||
Diabetes | 13(14.1%) | 3 (5.8%) | 1 (14.3%) | 2 (15.4%) | 7 (35.0%) | 0.018 |
Hypertension | 14 (15.2%) | 3 (5.8%) | 3 (42.8%) | 1 (7.7%) | 7 (35.0%) | 0.020 |
Cataract | 64 (69.6%) | 37 (71.2%) | 5 (71.4%) | 8 (50.0%) | 14 (51.8%) | 0.92 |
Intraocular pressure | ||||||
Hyper | 12 (11.8%) | 6 (11.5%) | 2 (28.6%) | 2 (12.5%) | 2 (7.4%) | 0.816 |
Normal | 64 (62.7%) | 32 (61.5%) | 3 (42.8%) | 11 (68.8%) | 18 (66.7%) | |
Hypo | 24 (23.5%) | 12 (23.1%) | 2 (28.6%) | 3 (18.8%) | 7 (25.9%) | |
No data | 2 (2.0%) | 2 (3.8%) | ||||
Mixed infections of bacteria and fungi | 39 (38.2%) | 23 (44.2%) | 3 (42.8%) | 6 (37.5%) | 7 (25.9%) | 0.459 |
Corneal infiltrate | 60 (58.8%) | 42 (80.8%) | 7 (100.0%) | 5 (31.2%) | 6 (22.2%) | <0.001 |
Positive samples | ||||||
Vitreous humor | 68 (66.7%) | 34 (65.4%) | 4 (57.1%) | 11 (68.8%) | 19 (70.4%) | 0.021 |
Aqueous humor | 18 (17.6%) | 11 (21.2%) | 4 (21%) | 2 (12.5%) | 1 (3.7%) | |
Cornea | 6 (5.9%) | 4 (7.7%) | 2 (28.6%) | |||
Secretion | 10 (9.8%) | 9 (17.3%) | 1 (14.3%) | |||
Intraocular foreign body | 3 (2.9%) | 3 (5.8%) | ||||
Other | 11 (10.8%) | 4 (7.7%) | 3 (42.8%) | 2 (12.5%) | 2 (7.4%) | |
Mean latent period (days) (median, IQR) | 16.5 (4, 48.75) | 14 (2.5, 30.5) | 60 (17, 61.5) | 19 (7, 29.9) | Unknown | 0.809 |
Length of hospitalization (days) (median, IQR) | 6 (4, 10) | 5 (3, 9) | 16 (4.5, 17.5) | 3 (1, 5) | 3 (1.75, 5) | 0.023 |
Organism | Total | Post-Trauma | Postoperative | Endogenous | Other |
---|---|---|---|---|---|
Fusarium species | 3 (3.3%) | 1 (1.1%) | 2 (2.2%) | ||
F. verticillioides | 1 (1.1%) | 1 (1.1%) | |||
F. solani | 1 (1.1%) | 1 (1.1%) | |||
Other Fusarium spp. | 1 (1.1%) | 1 (1.1%) | |||
Aspergillus species | 38 (41.3%) | 31 (33.3%) | 4 (4.3%) | 2 (2.2%) | 1 (1.1%) |
A. niger | 3 (3.3%) | 3 (3.2%) | |||
A. flavus | 2 (2.2%) | 2 (2.2%) | |||
A. fumigatus | 1 (1.1%) | 1 (1.1%) | |||
Other Aspergillus spp. | 32 (34.8%) | 25 (26.9%) | 4 (4.3%) | 2 (2.2%) | 1 (1.1%) |
Candida species | 28 (30.4%) | 4 (4.3%) | 2 (2.2%) | 9 (9.7%) | 13(14.0%) |
C. albicans | 16 (17.2%) | 1 (1.1%) | 1 (1.1%) | 6 (8.6%) | 8 (8.6%) |
C. tropicalis | 1 (1.1%) | 1 (1.1%) | |||
C. famata | 1 (1.1%) | 1 (1.1%) | |||
C. parapsilosis | 2 (2.2%) | 1 (1.1%) | 1 (1.1%) | ||
Other Candida spp. | 8 (8.6%) | 2 (2.2%) | 2 (2.2%) | 4 (4.3%) | |
Unidentified species | 24 (26.9%) | 17 (18.3%) | 1 (1.1%) | 2 (2.2%) | 4 (4.3%) |
Total | 93 | 53 | 7 | 13 | 20 |
Treatment Plan | Total 92/102 | Post-Trauma 52/52 | Postoperative 7/7 | Endogenous 13/16 | Other 20/27 | p Value |
---|---|---|---|---|---|---|
Total of pars plana vitrectomy | 109 | 62 | 6 | 15 | 26 | 0.232 |
Times of pars plana vitrectomy (mean, SD) | 1.1 ± 0.6 | 1.2 ± 0.7 | 0.8 ± 0.7 | 0.9 ± 0.2 | 1.0 ± 0.3 | |
Initial vitrectomy instead of biopsy | 86 (84.3%) | 43 (82.7%) | 3 (42.8%) | 15 (93.8%) | 25 (92.6%) | 0.053 |
Only vitreous biopsy and antimicrobial injections | 10 (9.8%) | 5 (9.6%) | 2 (28.6%) | 1 (6.2%) | 2 (7.4%) | |
First intravitreal injection of antimicrobials | 0.001 | |||||
Voriconazole + antibiotics | 8 (7.8%) | 5 (9.6%) | 2 (12.5%) | 1 (3.7%) | ||
Amp B + antibiotics | 13 (12.7%) | 11 (21.2%) | 1 (14.3%) | 1 (6.2%) | ||
Only antibiotics | 19 (18.6%) | 16 (30.8%) | 1 (14.3%) | 1 (6.2%) | 1 (3.7%) | |
Only voriconazole | 30 (29.4%) | 9 (17.3%) | 2 (28.6%) | 6 (37.5%) | 13 (48.1%) | |
Only Amp B | 30 (28.4%) | 11 (21.2%) | 2 (28.6%) | 5 (31.2%) | 12 (44.4%) | |
Simultaneous intravitreal injection of Amp B and voriconazole | 2 (2.0%) | 1 (14.3%) | 1 (6.2%) | |||
Time interval from start of clinical symptom to intravitreal injection of antifungal drugs | 20 (7, 37.25) | 8.5 (3, 20.25) | 15 (6.5, 56) | 23 (12.5 61.25) | 31 (21.5, 51.5) | 0.012 |
Times of intravitreal injection of antifungal drugs (median, IQR) | 1 (1, 2) | 1 (1, 2) | 3 (2.5, 4) | 1.2 ± 0.4 | 1.1 ± 0.3 | 0.002 |
Systemic antifungal drugs | 64 (69.6%) | 35 (67.3%) | 6 (85.7%) | 8 (61.5%) | 15 (75.0%) | 0.186 |
Itraconazole | 36 (39.1%) | 20 (38.5%) | 2 (28.6%) | 4 (30.8%) | 10 (50.0%) | |
Voriconazole | 10 (10.9%) | 5 (9.6%) | 3 (42.8%) | 2 (10.0%) | ||
First use voriconazole, then use itraconazole | 18 (19.6%) | 10 (19.2%) | 1 (14.3%) | 4 (30.8%) | 3 (15.0%) | |
Topical antifungal drugs | 61 (59.8%) | 42 (80.8%) | 6 (85.7%) | 6 (37.5%) | 7 (25.9%) | <0.001 |
Topical steroids drugs | 69 (67.6%) | 35 (67.3%) | 2 (28.6%) | 11 (68.8%) | 21 (77.8%) | 0.104 |
Intravitreal injection of steroids | 59 (57.8%) | 27 (51.9%) | 4 (57.1%) | 11 (68.8%) | 17 (63.0%) | 0.611 |
Final BCVA (logMAR) | Initial BCVA (logMAR), n | |||||||
---|---|---|---|---|---|---|---|---|
NA | NLP | LP | HM | FC | FC-20/400 | ≥20/400 | Total | |
NA | 3 | 1 | 6 | 1 | 1 | 0 | 0 | 12 |
Enucleated | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 5 |
NLP | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 5 |
LP | 0 | 0 | 7 | 3 | 0 | 0 | 0 | 10 |
HM | 1 | 0 | 7 | 16 | 3 | 0 | 0 | 27 |
FC | 0 | 0 | 3 | 4 | 1 | 0 | 0 | 8 |
≥20/400 | 1 | 0 | 4 | 12 | 6 | 5 | 7 | 35 |
Total | 5 | 1 | 35 | 38 | 11 | 5 | 7 | 102 |
Factor | BCVA (logMAR) | ||
---|---|---|---|
OR | 95% CI | p Value | |
Initial vision ≥ finger counting | 5.811 | 1.126–29.993 | 0.036 |
Absence of corneal infiltrate | 10.131 | 2.289–44.834 | 0.002 |
Not Aspergillus infection | 6.325 | 1.519–26.346 | 0.011 |
Trauma | 0.255 | 0.052–1.262 | 0.094 |
Normal intraocular pressure | 0.763 | 0.188–3.087 | 0.704 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, X.; Chen, Z.; Zhang, X.; Zhou, Z.; Boost, M.; Huang, T.; Zhou, X. Fungal Endophthalmitis: Clinical Characteristics, Pathogens, and Factors Affecting Visual Outcome. Antibiotics 2024, 13, 199. https://doi.org/10.3390/antibiotics13030199
Li X, Chen Z, Zhang X, Zhou Z, Boost M, Huang T, Zhou X. Fungal Endophthalmitis: Clinical Characteristics, Pathogens, and Factors Affecting Visual Outcome. Antibiotics. 2024; 13(3):199. https://doi.org/10.3390/antibiotics13030199
Chicago/Turabian StyleLi, Xiaoxia, Zhi Chen, Xiuwen Zhang, Zimei Zhou, Maureen Boost, Taomin Huang, and Xingtao Zhou. 2024. "Fungal Endophthalmitis: Clinical Characteristics, Pathogens, and Factors Affecting Visual Outcome" Antibiotics 13, no. 3: 199. https://doi.org/10.3390/antibiotics13030199
APA StyleLi, X., Chen, Z., Zhang, X., Zhou, Z., Boost, M., Huang, T., & Zhou, X. (2024). Fungal Endophthalmitis: Clinical Characteristics, Pathogens, and Factors Affecting Visual Outcome. Antibiotics, 13(3), 199. https://doi.org/10.3390/antibiotics13030199